Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
96.73
+0.85 (+0.89%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,524,700
Open
96.28
Bid (Size)
95.05 (1)
Ask (Size)
98.44 (1)
Prev. Close
95.88
Today's Range
96.15 - 97.20
52wk Range
89.81 - 108.78
Shares Outstanding
N/A
Dividend Yield
3.59%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
March 26, 2024
As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund
March 25, 2024
Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation.
Via
Benzinga
Performance
YTD
-4.23%
-4.23%
1 Month
-6.22%
-6.22%
3 Month
-3.24%
-3.24%
6 Month
-5.47%
-5.47%
1 Year
+7.25%
+7.25%
More News
Read More
1 Magnificent Dividend Stock to Buy and Hold
March 24, 2024
Via
The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Via
Talk Markets
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
March 22, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
2 Dividend Stocks to Buy and Hold Forever
February 29, 2024
Via
The Motley Fool
5 Tips to Manage Heart Health After a Heart Attack
February 23, 2024
Via
Brandpoint
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Via
Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Via
Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
Via
Benzinga
Exposures
Product Safety
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
Via
FinancialNewsMedia
Looking Into Novartis's Recent Short Interest
February 22, 2024
Via
Benzinga
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
Via
Benzinga
3 Dividend Stocks to Buy Hand Over Fist in March
March 10, 2024
Via
The Motley Fool
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
Via
Benzinga
Exposures
Product Safety
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Via
Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Via
Benzinga
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
Via
Benzinga
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children
March 04, 2024
Via
Benzinga
3 Stocks Primed for Exponential Returns by 2034
March 01, 2024
Via
InvestorPlace
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
Via
Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Via
Newsfile
Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment
February 26, 2024
Via
Investor's Business Daily
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
Via
Benzinga
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.